Compare Nokia Corp (NOK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nokia Corp trades at $9.32 (market cap $54.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Nokia Corp is far larger — about 7.4× Spyre Therapeutics Inc. Common Stock's market cap, and Nokia Corp pays a 1.74% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 65 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NOK | SYRE | |
|---|---|---|
Market Cap | $54.48B | $7.35B |
Volume | 85,996,980 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $16.83 | $108.92 |
52-Week Low | $5.55 | $22.18 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.50B | $6.35B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI, satellite communications, and network automation, including an expanded collaboration with Microsoft announced on September 17, 2026.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (59.6%) and a consensus price target of $17.50, implying significant upside. Key opportunities include growth in AI and cloud infrastructure demand, while risks involve competitive pressures and inconsistent earnings performance. Cash flow volatility remains a concern, with net cash flow negative in 2025 and 2026.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
